Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.
Biostatistics and Bioinformatics Core, Oregon National Primate Research Center, Biostatistics Shared Resource, Knight Cancer Institute, Portland, Oregon, USA.
Clin Infect Dis. 2021 Jan 27;72(2):285-292. doi: 10.1093/cid/ciaa017.
The World Health Organization (WHO) does not recommend routine adult booster vaccination for tetanus and diphtheria after completion of the childhood vaccination series. However, many countries continue to implement adult booster vaccinations, leading to the question of whether this is necessary to reduce the incidence of these 2 rare diseases.
We conducted an observational cohort study based on WHO case reports from 2001 through 2016. We compared the incidence of tetanus and diphtheria in 31 North American and European countries that either do or do not recommend adult booster vaccination.
Countries that vaccinate adults every 5-20 years (group 1) were compared with countries that do not routinely vaccinate adults for tetanus or diphtheria (group 2). Comparison of group 1 vs group 2 revealed no significant decline in tetanus incidence rates among countries that vaccinate adults (P = .52; risk ratio [RR] = 0.78; 95% confidence interval [CI], .36 to 1.70). The risk of contracting diphtheria was increased among countries that vaccinate adults due to inclusion of Latvia, a country that had poor vaccination coverage (P < .001). However, if Latvia is excluded, there is no difference in diphtheria incidence between countries that do or do not routinely vaccinate adults (P = .26; RR = 2.46; 95% CI, .54 to 11.23).
Review of >11 billion person-years of incidence data revealed no benefit associated with performing adult booster vaccinations against tetanus or diphtheria. Similar to other vaccines, this analysis supports the WHO position on adult booster vaccination and, if approved by governing health authorities, this may allow more countries to focus healthcare resources on vulnerable and undervaccinated populations.
世界卫生组织(WHO)不建议在完成儿童疫苗接种系列后对破伤风和白喉进行常规成人加强免疫接种。然而,许多国家仍继续实施成人加强免疫接种,这引发了一个问题,即是否有必要减少这两种罕见疾病的发病率。
我们基于 2001 年至 2016 年期间 WHO 的病例报告进行了一项观察性队列研究。我们比较了 31 个北美和欧洲国家的破伤风和白喉发病率,这些国家要么推荐成人加强免疫接种,要么不推荐。
每 5-20 年对成人进行疫苗接种的国家(第 1 组)与不常规对成人进行破伤风或白喉疫苗接种的国家(第 2 组)进行了比较。第 1 组与第 2 组的比较显示,对成人进行疫苗接种的国家破伤风发病率没有显著下降(P=.52;风险比 [RR] = 0.78;95%置信区间 [CI],.36 至 1.70)。由于包括疫苗接种覆盖率较差的拉脱维亚在内,对成人进行疫苗接种的国家白喉发病风险增加(P<.001)。然而,如果排除拉脱维亚,那么不常规对成人进行疫苗接种的国家与常规接种的国家之间的白喉发病率没有差异(P=.26;RR = 2.46;95% CI,.54 至 11.23)。
对超过 110 亿人年的发病率数据进行审查后,未发现与破伤风或白喉进行成人加强免疫接种相关的益处。与其他疫苗类似,这项分析支持了 WHO 对成人加强免疫接种的立场,如果得到管理卫生当局的批准,这可能使更多国家能够将医疗保健资源集中在脆弱和未充分接种疫苗的人群上。